Stockreport

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress [Yahoo! Finance]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF On March 13, Bank of America Securities maintained a Buy rating on Mineralys Therapeutics Inc. (NASDAQ:MLYS). The firm increased its price target to $51 from $46, citin [Read more]